Please assess the completion status of the following clinical trial:

Trial Title: Prospective, Comparative Assessment of Alveolar Bone Augmentation Using GUIDOR® Membrane in the Bound Edentulous Space

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent~2. ≥ 21 years and ≤ 75 years~3. In need of one or more implants replacing missing or non-restorable teeth in the maxilla within region 14 to 24 or the mandible within region 34 to 44~4. Edentulous for at least 6 months at study site~5. A buccal-lingual ridge width at study site of ≤ 4 mm~6. A mesial-distal distance between adjacent teeth at study site at bone level of at least 5 mm~7. A keratinized mid-buccal mucosal thickness of at least 2 mm at study site (measured buccally at MD midline from the mucogingival junction to the projected alveolar ridge crest)~8. Teeth adjacent (mesial and distal) to study site must consist of two stable, natural teeth without signs of periodontal bone loss (\> 3 mm) and/or significant soft tissue loss~9. A minimum of twenty teeth in good repair~Exclusion Criteria:~1. Insufficient interocclusal distance for implant placement and restoration at study site~2. More than 3 mm vertical bone loss at study site as measured from the mid-buccal crest of bone on the adjacent teeth~3. Previous site development (soft and/or bone tissue) performed at the study site~4. Untreated rampant caries and uncontrolled periodontal disease~5. A history within the last 6 months of the daily use of any non-cigarette tobacco products (smokeless chewing tobacco, e-cigarette, pipe or cigar smoking), or of smoking more than 10 cigarettes per day.~6. Current alcohol dependency, alcohol abuse or chemical dependency based on DSM-IV Criteria or drug abuse~7. Subjects having uncontrolled endocrine-induced diseases (e.g. uncontrolled diabetes mellitus)~8. Systemic or local disease or condition that would compromise post-operative healing and/or osseointegration~9. Use of any substance or medication that will influence bone metabolism (e.g. intravenous bisphosphonates)~10. Need for systemic corticosteroids or any other medication that would influence post-operative healing and/or osseointegration~11. History of radiation in the head and neck region~12. Subject is pregnant as reported at time of enrollment~13. Unable or unwilling to return for follow-up visits for a period of 6 months~14. Unlikely to be able to comply with study procedures according to Investigators judgement~15. Previous enrollment or randomization of treatment in the present study~16. Involvement in the planning/conduct of the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- GUIDOR® membrane with FDBA (Type: ACTIVE_COMPARATOR): horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
- GUIDOR® membrane alone (Type: ACTIVE_COMPARATOR): horizontal bone augmentation with synthetic GUIDOR® membrane
- Bio-Gide® membrane with FDBA (Type: ACTIVE_COMPARATOR): xenograft BioGide® membrane + FDBA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues